Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients (Q39455513)

12 September 2017

Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients (English)

1 reference

12 September 2017

0 references

1 reference

Herman A Perroud

1

1 reference

12 September 2017

Maria José Rico

2

1 reference

12 September 2017

Carlos M Alasino

3

1 reference

12 September 2017

Francisco Queralt

4

1 reference

12 September 2017

Leandro E Mainetti

5

1 reference

12 September 2017

Stella M Pezzotto

6

1 reference

12 September 2017

Viviana R Rozados

7

1 reference

12 September 2017

O Graciela Scharovsky

8

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 March 2013

1 reference

12 September 2017

1 reference

12 September 2017

9

1 reference

12 September 2017

3

1 reference

12 September 2017

451-462

1 reference

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

12 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Angiogenesis in life, disease and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Metronomic chemotherapy: new rationale for new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Quantity and clinical relevance of circulating endothelial progenitor cells in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Pilot study of a pediatric metronomic 4-drug regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.196

21 January 2018

Identifiers

DOI

10.2217/FON.12.196

1 reference

12 September 2017

1 reference